Welcome to our dedicated page for Filana Therapeutics news (Ticker: FLNA), a resource for investors and traders seeking the latest updates and insights on Filana Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Filana Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Filana Therapeutics's position in the market.
Filana Therapeutics (NASDAQ: FLNA) reported 2025 results and a business update focused on its TSC-related epilepsy program and capital efficiency.
The company posted a net loss of $91.0 million ($1.88 per share) for 2025, year-end cash of $95.5 million and estimates cash of $47–$50 million at June 30, 2026. Filana is addressing FDA requests tied to a December 2025 clinical hold and expects to submit a response as soon as practicable.
Filana Therapeutics (NASDAQ: FLNA) is the new corporate name formerly known as Cassava Sciences, effective March 11, 2026.
The rebranding aligns the company with its strategic focus on developing medicines that modulate the filamin A protein to address CNS disorders, including Tuberous Sclerosis Complex-related epilepsy. The updated website is available at https://www.filanatx.com.